Drugs for Congestive Heart Failure
This article was originally published in Start Up
A drug maker with a new CHF treatment will be helping to fill a serious unmet clinical need and benefiting from a huge, chronic care market. But development costs are huge and risks are high: the clinical history is lined with failed drugs. Thus, most CHF drug projects are in large companies; biotechs cluster at the pre-compound discovery end.
You may also be interested in...
Looking for larger patient populations, the newer CHF device companies position their products as early intervention tools that can perhaps delay or halt the progression of the disease.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.